This Program Project in Clinical Cancer Research contains three independent but closely interactive research components, and four cores. The research components are Developmental Therapy, Hematologic Malignancies and Solid Tumors. The cores are administration, biostatistics, pharmacology laboratory, and a genetics core. The long term objective of this research program is to contribute to the development of more effective treatment for patients with cancer. The general approach we propose to continue to use to achieve this objective is 1) introduce new drugs and promising new concepts into clinical studies; 2) to carry out the clinical studies with care, compassion and precision, with active collaboration of the Center's laboratory and biostatistical scientists in study design and evaluation. New drugs and biologicals will be obtained from 1) the laboratories of the Sloan-Kettering Institute and from extra-mural scientists with whom the center has active collaboration 2) the drug development program of the National Cancer Institute; 3) the pharmaceutical industry. With drugs synthesized within this center, preclinical evaluation including studies of mechanism of action, drug metabolism and preclinical toxicology will be carried out within the center. The drugs are studied in Phase I trials intensively by the Developmental Therapy project (project 1) with the help of the pharmacology core laboratory. Phase II trials are carried out by the hematology and solid tumor programs. Therapeutically active agents are entered into multidrug combinations and multidisciplinary treatment programs. A large patient population allows thorough testing of drugs and concepts in a variety of hematologic and solid tumors. The program also generates useful information on biochemical, cytokinetic and immunologic factors that have a bearing on the course of disease and response to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA005826-31
Application #
3092496
Study Section
Special Emphasis Panel (SRC (A1))
Project Start
1978-01-01
Project End
1994-11-30
Budget Start
1992-12-01
Budget End
1993-11-30
Support Year
31
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Tedeschi, Philip M; Vazquez, Alexei; Kerrigan, John E et al. (2015) Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development. Mol Cancer Res 13:1361-6
Bell, Melanie L; Kenward, Michael G; Fairclough, Diane L et al. (2013) Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ 346:e8668
Zhou, Ping; Hoffman, James; Landau, Heather et al. (2012) Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk 12:49-58
Rizvi, Naiyer A; Rusch, Valerie; Pao, William et al. (2011) Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res 17:3500-6
Zhao, Binsheng; Oxnard, Geoffrey R; Moskowitz, Chaya S et al. (2010) A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16:4647-53
Klimek, Virginia M; Fircanis, Sophia; Maslak, Peter et al. (2008) Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14:826-32
Riely, Gregory J; Kris, Mark G; Zhao, Binsheng et al. (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5
Zhao, Binsheng; Schwartz, Lawrence H; Moskowitz, Chaya S et al. (2006) Lung cancer: computerized quantification of tumor response--initial results. Radiology 241:892-8
Maslak, P; Chanel, S; Camacho, L H et al. (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20:212-7
Yankeelov, Thomas E; Rooney, William D; Huang, Wei et al. (2005) Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 18:173-85

Showing the most recent 10 out of 39 publications